| Bioactivity | GSK2200150A, identified by high-throughput screening (HTS) campaign, is an anti-tuberculosis (TB) agent. | ||||||||||||
| Target | MIC: 0.38 μM (M.tuberculosis strain H37Rv) | ||||||||||||
| Invitro | GSK2200150A is a novel antimycobacterial agent against Mycobacterium tuberculosis.The activities of GSK2200150A containing the spirocycle core are determined against the virulent M.tuberculosis strain (H37Rv) with MIC of 0.38 μM[1]. | ||||||||||||
| Name | GSK2200150A | ||||||||||||
| CAS | 1443138-53-1 | ||||||||||||
| Formula | C20H23NO3S | ||||||||||||
| Molar Mass | 357.47 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Badiola KA, et al. Efficient Synthesis and Anti-Tubercular Activity of a Series of Spirocycles: An Exercise in OpenScience. PLoS One. 2014 Dec 10;9(12):e111782. |